Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. TMO currently has a forward P/E ratio of 24.80, while IDXX has a forward P/E of ...

A few of its recent strategic acquisitions that are likely to drive future growth include its plan to acquire Olink Holdings for $26.00 per common share in cash, which was announced in October. The acquisition is expected to enhance Thermo Fisher's capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. Through the acquisition, the company expects to deliver $125 million in adjusted operating income synergies in the fifth year, driven by revenue synergies and ...

The new 65,000-square-foot space in Covington, KY, will expand the company's sample management and biorepository operations. The latest development will be in addition to its existing site in nearby Highland Heights. More on the News Thermo Fisher Scientific Inc. (TMO) recently announced the expansion of its central laboratory operations in Kentucky under its PPD clinical research business. The latest addition will help TMO to accelerate pharmaceutical and biotech customers' delivery of safe, effective medi ...

Thermo Fisher Scientific (TMO) recently unveiled the PlasmidPro Maxi Processor (PlasmidPro), its latest addition to the Thermo Scientific KingFisher instrument portfolio. The solution has a comprehensive range of key features that sets it apart as the only fully automated maxi-scale plasmid DNA (pDNA) purification system. Image Source: Zacks Investment Research Thermo Fisher is addressing the rapidly growing demand for plasmid DNA purification for emerging therapies with a new 'press and go' solution to spe ...

Thermo Fisher Scientific Inc. (TMO) has announced a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, WI, under its PPD clinical research business. The addition of a 72,500-square-foot building is likely to improve the company's clinical development and laboratory services by expanding the site's chemistry, manufacturing and control (CMC) analytical capabilities. This, in turn, should help its customers provide high quality and safety standards for patient ...

Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produce vaccines and therapies globally. Thermo Fisher's business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augmen ...

Thermo Fisher Scientific (TMO) recently introduced the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators to support the future implementation of workflow automation in cell therapy production. These first-of-their-kind CO2 incubators are designed for integration into automated and modular laboratories. The latest development from Thermo Fisher represents the most advanced incubators in the VIOS portfolio. The company's VIOS family of incubators is known for optimal cell growth conditions and minimal c ...

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Thermo Fisher Scientific Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) The report covers detailed informatio ...

through a tough time that might impact their academic budgets. Thermo Fisher remains cautious since growth could further moderate if the economic scenario worsens. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has moved to $21.65 from $21.64 in the past 30 days. Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS) , Medpace (MEDP) and ResMed (RMD) . Medpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared ...

narvikk Introduction On April 24, I wrote an article covering Alexandria Real Estate Equities (ARE), a REIT that owns healthcare real estate, including laboratories. This REIT is on my radar as a fantastic way to benefit from innovation in healthcare without having to figure out which biotech company will reveal a groundbreaking drug next. [...] the company has provided the facilities that allowed for groundbreaking research, as the company noted that roughly half of all FDA-approved therapies over the past ...